Please login to the form below
TiGenix
This page shows the latest TiGenix news and features for those working in and with pharma, biotech and healthcare.
Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy
Alofisel, which works by a local administration of allogeneic expanded adipose-derived stem cells (eASCs), was initially manufactured at Belgian biopharma TiGenix, which entered into a licensing agreement with Takeda. ... TiGenix has another
Latest news
-
Takeda offers €520m for stem cell firm TiGenix
Takeda has launched a takeover bid for Belgian biotech TiGenix, which has completed late-stage testing of a stem cell therapy for Crohn’s disease-related complications. ... The Japanese pharma company says it intends to buy voting-right shares in
-
CHMP backs Europe’s first allogeneic stem cell therapy
Takeda has ex-US rights to the Crohn's disease treatment from biotech TiGenix. ... TiGenix still owns the US rights to Cx601, considered a larger market opportunity for the therapy than Europe.
-
TiGenix’s Crohn's fistulas treatment wins orphan drug status
FDA designation follows positive trial results. Belgian biopharmaceutical group TiGenix is one step closer to getting its first-in-class Crohn’s fistulas disease treatment to the US market following an ... Meanwhile, TiGenix and partner Takeda has said
-
TiGenix cell therapy for Crohn's fistulas shows long-term benefit
Belgian biotech TiGenix has racked up another positive result for its Takeda-partnered stem cell therapy for fistulas caused by Crohn's disease. ... After 52 weeks the clinical remission rate was 59% and 42%, respectively, with three quarters of patients
More from news
Approximately 5 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
A few days later Takeda announced it was paying $628m (82% share price premium) to buy Belgian company TiGenix NV and its lead asset Cx601 (darvadstrocel), an allogeneic stem cell therapy ... Option exercise (2 options). 640. TiGenix/Takeda. Cx601, lead
-
Deal Watch July 2016
Other deals where the licensee has committed real upfront money include Takeda's $28m upfront payment for ex-US rights to TiGenix's Cx601, a suspension of allogeneic adipose-derived stem ... Acquisition. 416. TiGenix/ Takeda. Cx601 - Stem cell treatment
-
Pharma deals in July 2015
At the most extreme in terms of a low upfront is the $7m paid by Tigenix in the $293m acquisition of Coretherapix, presumably because stem cell therapies are high risk. ... Coretherapix / Tigenix. Company acquisition. Cardiac stem cell in Phase 2.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Bone Therapeutics strengthens board with new chairman
Jean Stéphenne joins the cell therapy company from TiGenix. Belgian biotechnology company Bone Therapeutics has appointed Jean Stéphenne as its new chairman of the board of directors, succeeding Steve Swinson in ... Stéphenne’s career history has
-
Belgium's TiGenix appoints Dr Gregory Gordon
Belgium biopharma firm TiGenix has appointed Dr Gregory Gordon to head up its US medical department as part of moves to strengthen its stateside operations. ... Meanwhile, Valles-Sukkar arrives at TiGenix from Alexion Pharmaceuticals, where she was
-
Eduardo Bravo becomes head of EBE
TiGenix CEO appointed president of the EBE’s board of directors. The European Biopharmaceutical Enterprises (EBE) has appointed Eduardo Bravo as president of its board of directors for the 2016-2018 ... He c urrently serves as chief executive officer
-
TiGenix appoints Dr Marie Paule Richard
Belgium-based cell therapy company TiGenix has appointed Dr Marie Paule Richard as its new chief medical officer. ... We are very fortunate to have biopharma development, regulatory and commercialisation heavyweight Marie Paule joining the TiGenix
More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
- Want the most from your Pharmaceutical portfolio?
- Diversity and inclusion in clinical trials: keeping up momentum
- 10 Important Advisor Questions: Placement of Your Product in the Current/Future Treatment Algorithm
- Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia
No results were found
PMHub
Kardex
Kardex is a global industry partner for intralogistics solutions and a leading supplier of automated storage solutions and material handling...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
